Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 156

1.

Optimizing the treatment of haemophilia B: laboratory and clinical perspectives.

Aledort LM.

Haemophilia. 2010 Jul;16 Suppl 6:1-2. doi: 10.1111/j.1365-2516.2010.02298.x.

PMID:
20561350
2.

Haemophilia B: current pharmacotherapy and future directions.

Franchini M, Frattini F, Crestani S, Bonfanti C.

Expert Opin Pharmacother. 2012 Oct;13(14):2053-63. doi: 10.1517/14656566.2012.721780. Epub 2012 Sep 4. Review.

PMID:
22946758
3.
4.

Recombinant factor IX for clinical and research use.

Monahan PE, Di Paola J.

Semin Thromb Hemost. 2010 Jul;36(5):498-509. doi: 10.1055/s-0030-1255444. Epub 2010 Jul 14. Review.

PMID:
20632248
5.
6.

Current management of hemophilia B: recommendations, complications and emerging issues.

Franchini M.

Expert Rev Hematol. 2014 Oct;7(5):573-81. doi: 10.1586/17474086.2014.947955. Epub 2014 Aug 12. Review.

PMID:
25112898
7.

Continuous intravenous infusion of a plasma-derived factor IX concentrate (Mononine) in haemophilia B.

Hoots WK, Leissinger C, Stabler S, Schwartz BA, White G, Dasani H, Massion C, Negrier C, Schindel F, Schulman S.

Haemophilia. 2003 Mar;9(2):164-72.

PMID:
12614367
8.

Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates.

Roth DA, Kessler CM, Pasi KJ, Rup B, Courter SG, Tubridy KL; Recombinant Factor IX Study Group.

Blood. 2001 Dec 15;98(13):3600-6.

9.

[Prophylaxis in haemophilia B. Prevention of bleeds and FIX consumption].

Siegmund B, Richter H, Pollmann H.

Hamostaseologie. 2010 Nov;30 Suppl 1:S35-8. German.

PMID:
21042666
10.

Evidence-based use of recombinant FVIIa (NovoSeven, NiaStase) for the treatment of hemophilia with inhibitors in children and adolescents.

Goldstein B, Geldziler B, Bjerre J, Seremetis S.

Transfus Apher Sci. 2008 Feb;38(1):25-32. doi: 10.1016/j.transci.2007.12.002. Epub 2008 Feb 11. Review.

PMID:
18267372
11.

The overall effectiveness of prophylaxis in severe haemophilia.

Panicker J, Warrier I, Thomas R, Lusher JM.

Haemophilia. 2003 May;9(3):272-8.

PMID:
12694517
12.

Expression and characterization of a novel human recombinant factor IX molecule with enhanced in vitro and in vivo clotting activity.

Perot E, Enjolras N, Le Quellec S, Indalecio A, Girard J, Negrier C, Dargaud Y.

Thromb Res. 2015 May;135(5):1017-24. doi: 10.1016/j.thromres.2015.02.034. Epub 2015 Mar 10.

PMID:
25795563
13.

Factor IX inhibitors and anaphylaxis in hemophilia B.

Warrier I, Ewenstein BM, Koerper MA, Shapiro A, Key N, DiMichele D, Miller RT, Pasi J, Rivard GE, Sommer SS, Katz J, Bergmann F, Ljung R, Petrini P, Lusher JM.

J Pediatr Hematol Oncol. 1997 Jan-Feb;19(1):23-7.

PMID:
9065715
14.

Cost-of-illness study of severe haemophilia A and B in five French haemophilia treatment centres.

Nerich V, Tissot E, Faradji A, Demesmay K, Bertrand MA, Lorenzini JL, Briquel ME, Pouzol P, Woronoff-Lemsi MC.

Pharm World Sci. 2008 Jun;30(3):287-92. Epub 2007 Dec 18.

PMID:
18085428
15.

Half-life extension through albumin fusion technologies.

Schulte S.

Thromb Res. 2009 Dec;124 Suppl 2:S6-8. doi: 10.1016/S0049-3848(09)70157-4.

PMID:
20109653
16.

Reformulated BeneFix: efficacy and safety in previously treated patients with moderately severe to severe haemophilia B.

Lambert T, Recht M, Valentino LA, Powell JS, Udata C, Sullivan ST, Roth DA.

Haemophilia. 2007 May;13(3):233-43. Erratum in: Haemophilia. 2007 Jul;13(4):450.

PMID:
17498071
17.

Safety and efficacy of investigator-prescribed BeneFIX prophylaxis in children less than 6 years of age with severe haemophilia B.

Monahan PE, Liesner R, Sullivan ST, Ramirez ME, Kelly P, Roth DA.

Haemophilia. 2010 May;16(3):460-8. doi: 10.1111/j.1365-2516.2009.02162.x. Epub 2010 Jan 4.

PMID:
20059559
18.

An open clinical study assessing the efficacy and safety of Factor IX Grifols, a high-purity Factor IX concentrate, in patients with severe haemophilia B.

Lissitchkov T, Matysiak M, Zawilska K, Gercheva L, Antonov A, Montañes M, Paez A.

Haemophilia. 2010 Mar;16(2):240-6. doi: 10.1111/j.1365-2516.2009.02090.x. Epub 2009 Dec 14.

PMID:
20015218
19.

Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B.

Negrier C, Knobe K, Tiede A, Giangrande P, Møss J.

Blood. 2011 Sep 8;118(10):2695-701. doi: 10.1182/blood-2011-02-335596. Epub 2011 May 9.

20.

Switching to recombinant factor IX Fc fusion protein prophylaxis results in fewer infusions, decreased factor IX consumption and lower bleeding rates.

Powell J, Shapiro A, Ragni M, Negrier C, Windyga J, Ozelo M, Pasi J, Baker R, Potts J, Li S, Mei B, Pierce GF, Robinson B.

Br J Haematol. 2015 Jan;168(1):113-23. doi: 10.1111/bjh.13109. Epub 2014 Sep 11.

PMID:
25209873

Supplemental Content

Support Center